Opinion: STAT+: BridgeBio CEO: Congress must renew a popular, bipartisan FDA program benefiting sick kids

In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher program — are falling by the wayside, writes BridgeBio’s Neil Kumar.